Every 8-K that Zymeworks Inc. (ZYME) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ZYME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZYME filings page.
Zymeworks Inc. (ZYME) announced that its partner Jazz Pharmaceuticals received U.S. FDA approval for two Ziihera® (zanidatamab-hrii)-containing regimens as first-line treatments for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The regimens combine Ziihera with Tevimbra® and chemotherapy, or with chemotherapy alone, across defined HER2+ patient groups.
Under Zymeworks’ License and Collaboration Agreement with Jazz, this approval triggers a $250 million milestone payment. Zymeworks remains eligible for up to $1.3 billion in additional regulatory and commercial milestones and tiered royalties of 10% to 20% on Jazz’s net sales of zanidatamab in Jazz’s territories. Through a separate collaboration with BeOne Medicines, Zymeworks has received $81 million to date and may earn up to an additional $144 million in milestones plus tiered royalties of up to 19.5% on net sales in BeOne’s territories. Zymeworks states that these partnered cash flows support its strategy to fund a wholly owned pipeline of trispecific T‑cell engagers and antibody‑drug conjugates.
Zymeworks Inc. reported second-quarter 2026 results and a broad corporate update as it evolves into a diversified, revenue-generating biotechnology business. Total revenue was $4.6 million, compared with $48.7 million a year earlier, mainly because 2025 included significant non-recurring collaboration milestones and higher development support and drug supply revenue from Jazz. Research and development expenses declined to $27.4 million, while general and administrative expenses increased to $19.3 million, largely from higher stock-based compensation. Interest on a royalty-backed note financing with Royalty Pharma contributed to net other expense of $3.1 million, and the company posted a net loss of $45.0 million versus net income of $2.3 million in the prior-year quarter.
Cash, cash equivalents and marketable securities totaled $322.5 million as of June 30, 2026. Under its 2026 share repurchase program of up to $125.0 million, Zymeworks had used $49.4 million to buy 1,971,454 shares at an average price of $25.04, and since August 2024 has cumulatively repurchased $213.6 million of stock, leaving about 71.0 million shares outstanding. Strategically, an August 25, 2026 U.S. PDUFA target action date for zanidatamab could trigger a $250 million approval milestone, the first of up to $440 million in potential global regulatory milestones. The proposed acquisition of Theravance Biopharma, expected to close in the second half of 2026 and financed primarily by a $350 million non-recourse note and Theravance’s anticipated $360 million net cash, is expected to be accretive to earnings and generate positive cash flow, adding YUPELRI royalties, additional royalty and milestone interests, an early-stage I&I portfolio and $2.5 billion in Irish tax attributes. Zymeworks plans to stop providing cash runway guidance and instead focus its outlook on operating performance and long-term growth metrics.
Zymeworks Inc. is acquiring Theravance Biopharma in a cash deal designed to add durable commercial cash flows and expand its royalty-driven model. Under a definitive merger agreement, Zymeworks will buy all Theravance shares for $17.00 per share in cash, valuing the transaction at approximately $929 million, plus a non‑tradeable contingent value right (CVR) for each share tied mainly to future monetization of ampreloxetine and related milestones.
The deal adds YUPELRI, the only once‑daily nebulized LAMA approved in the U.S. for COPD maintenance, to Zymeworks’ partnered portfolio. Zymeworks expects YUPELRI to provide an anticipated long‑duration and potentially growing cash‑flow stream alongside existing Ziihera cash flows. The company plans to complete Theravance’s previously announced restructuring to reduce R&D and G&A spending while largely preserving its hospital sales infrastructure.
Financing combines $350 million of new senior secured non‑recourse notes from OMERS Life Sciences, backed by Theravance’s 35% YUPELRI profit share (with 75% of that share used to service the debt), roughly $219 million of Zymeworks cash, and about $360 million of Theravance cash at closing. Both parties agreed to reciprocal $32.515 million termination fees in defined circumstances. Closing is targeted for the second half of 2026, subject to HSR clearance and approval by at least two‑thirds of Theravance shares present and voting.
Zymeworks Inc. has authorized a new 2026 share repurchase program allowing it to buy back up to $125.0 million of its common stock. The Board terminated the prior 2025 program, under which Zymeworks repurchased 4,197,553 shares at an average price of $24.36, totaling $102.3 million. As of May 13, 2026, the company had about 73.0 million common shares outstanding. Zymeworks states that, based on current plans and assuming full execution of the new program, existing cash as of March 31, 2026 plus anticipated regulatory milestone payments of $440.0 million related to potential Ziihera approvals are expected to fund operations beyond 2028.
Zymeworks Inc. reported first quarter 2026 results, with revenue of $2.4 million, down from $27.1 million a year earlier as prior non-recurring clinical milestone payments rolled off and collaboration and royalty revenue became the main drivers.
R&D expense was $34.5 million and G&A was $15.1 million, both slightly lower year over year, leading to a net loss of $44.2 million versus $22.6 million in 2025. Adjusted gross operating expense (non-GAAP) declined to $42.6 million from $46.3 million.
The company ended March 31, 2026 with $403.8 million in cash, cash equivalents and marketable securities and reiterated guidance for approximately $300 million in aggregate adjusted gross operating expenses over 2026–2028. It expects 2026 adjusted gross operating expenses to be about 20% lower than 2025 on a non-GAAP basis.
Zymeworks highlighted regulatory momentum for partnered HER2 antibody Ziihera (zanidatamab-hrii), including U.S. FDA Priority Review for first-line HER2-positive GEA with an August 25, 2026 PDUFA date and sBLA acceptances in China. Potential approval milestones across territories total $440 million.
The company continued to advance wholly owned ADC ZW191, reporting Phase 1 ovarian cancer data with confirmed objective response rates above 50% and high disease control rates, and presented a new RAS inhibitor ADC platform. It also used $95.8 million to repurchase 3.93 million shares under a $125 million buyback, leaving about 73.0 million shares outstanding.
Zymeworks Inc. appointed Kristin Stafford, age 44, as Executive Vice President and Chief Financial Officer, effective April 1, 2026. She becomes the company’s principal financial and principal accounting officer. Stafford previously held senior finance and accounting roles at Royalty Pharma, BioPharma Credit, Ernst & Young, iHeartMedia, and Deloitte and serves on Novocure’s board.
She entered into an employment agreement with Zymeworks Biopharmaceuticals Inc. with no fixed term, including change-in-control "parachute" protections structured to avoid excise tax without any tax gross-up from the company. Kenneth Galbraith ceased serving as interim CFO on the start date but continues as Chair, President, and Chief Executive Officer.
Zymeworks Inc. has entered into a $250 million non-recourse royalty-backed note financing with Royalty Pharma, using 30% of future worldwide tiered royalties on Ziihera (zanidatamab-hrii) from Jazz and BeOne as repayment collateral. The funding is structured through a special-purpose subsidiary that sold a 30% royalty interest and simultaneously borrowed $250 million under a term loan maturing on December 31, 2042.
The total amount payable under the loan is about $412.5 million if fully repaid on or before December 31, 2033, or approximately $481.3 million if repaid by final maturity, inclusive of interest, premiums, fees and other amounts. Zymeworks will retain 70% of Ziihera royalties during the repayment period, with full royalty rights reverting once Royalty Pharma’s capped return is reached, and it keeps all regulatory and commercial milestone payments, including up to $1.5 billion in potential remaining milestones tied to approvals and sales.
The loan is secured only by the subsidiary’s royalty assets and related equity interests, and Royalty Pharma has no recourse to other Zymeworks or Zymeworks BC assets under the agreement. The arrangements include customary covenants, restrictions on modifying key collaboration agreements for Ziihera, and events of default tied to termination of those agreements or a change of control of the company.
Zymeworks Inc. reported 2025 total revenue of $106.0 million, up 39% from 2024, and reduced its annual net loss by 34% to $81.1 million. Fourth-quarter revenue was $2.5 million with a net loss of $41.2 million.
The company ended 2025 with $270.6 million in cash, cash equivalents and marketable securities and has a new $250.0 million royalty-backed note from Royalty Pharma to support share repurchases, potential acquisitions and cash runway beyond 2028. Zymeworks has used $62.5 million of its current $125.0 million buyback authorization.
Management expects 2026 adjusted gross operating expenses to be about 20% lower than 2025’s $170.5 million (non-GAAP) and outlined multiple partnered milestones, including up to $440.0 million in potential regulatory milestones for Ziihera in gastroesophageal adenocarcinoma across major markets.
Zymeworks Inc. reported preliminary, unaudited cash resources of about $270.6 million as of December 31, 2025, and said that, based on current plans, it believes it can fund operations beyond 2028 assuming full execution of a $125.0 million share repurchase plan and receipt of $440.0 million in anticipated regulatory milestone payments tied to potential Ziihera approvals in GEA across the United States, Europe, Japan and China. The company also announced multiple leadership changes, including appointing Brian Cherry as a new Class II director, terminating Executive Vice President, Chief Business Officer and Chief Financial Officer Leone Patterson without cause, and naming Chair, President and CEO Kenneth Galbraith as interim Chief Financial Officer. Zymeworks promoted Mark Hollywood to Executive Vice President and Chief Operating Officer with increased salary and new equity awards, and outlined a planned transition in the Chief Medical Officer role from Jeffrey Smith, who is retiring, to Sabeen Mekan.
Zymeworks Inc. reported several updates. Director Scott Platshon resigned from the board effective immediately, and the company stated his resignation was not due to any disagreement over operations, policies, or practices. The company announced a strategic initiative to optimize future cash flows from Ziihera® (zanidatamab-hrii), other licensed products, and other healthcare assets. The board also authorized a $125.0 million share repurchase program for its common stock.
As part of its financial outlook, Zymeworks noted that, assuming full execution of the $125.0 million repurchase program, its existing cash resources of $299.4 million as of September 30, 2025, together with anticipated milestone payments tied to potential regulatory approvals of Ziihera in the United States, Europe, Japan and China, are expected to fund planned operations beyond 2028. Separately, the company announced the appointment of Mr. Platshon as Acting Chief Investment Officer.
Zymeworks Inc. (ZYME) announced positive topline Phase 3 results for its lead drug Ziihera® (zanidatamab-hrii). The HERIZON-GEA-01 trial evaluated Ziihera in combination with chemotherapy, with or without the PD‑1 inhibitor Tevimbra® (tislelizumab), as a first-line treatment for HER2‑positive locally advanced or metastatic gastroesophageal adenocarcinoma. This includes cancers of the stomach, gastroesophageal junction, and esophagus, an area of significant medical need. The positive topline outcome from this late‑stage study suggests Ziihera may have meaningful clinical activity in this setting, and further details are provided in the company’s November 17, 2025 press release.
Zymeworks Inc. (ZYME) furnished a press release announcing financial results for the three and nine months ended September 30, 2025. The release is attached as Exhibit 99.1 to a Form 8-K.
The information under Items 2.02 and 7.01 and Exhibit 99.1 is furnished and is not deemed “filed” for Section 18 of the Exchange Act or incorporated by reference, except as specifically stated. Zymeworks also notes it shares material updates via SEC filings, its websites, and official social media channels.
Zymeworks Inc. has decided to voluntarily discontinue clinical development of ZW171, a T cell engager targeting gynecological, thoracic, and digestive system cancers. The decision follows completion of the planned dose-escalation cohorts in a Phase 1 trial in patients with ovarian cancer and non-small cell lung cancer, where a maximum tolerated dose was established. After reviewing these results, the company concluded that further dose evaluation in the current trial was unlikely to support a benefit-risk profile consistent with the desired monotherapy target product profile. The decision was announced via press release furnished as an exhibit.
Zymeworks Inc. appointed Gregory A. Ciongoli and Robert E. Landry to its board effective August 10, 2025; Mr. Ciongoli was named a Class II director with a term expiring at the 2026 annual meeting and Mr. Landry was named a Class I director with a term expiring at the 2025 annual meeting. Both were added to the Audit Committee and will receive the companys standard non-employee director compensation, including an initial stock option grant to purchase 62,000 shares each.
Separately, the company entered into a private placement under which Mr. Ciongoli agreed to buy 415,000 shares at $12.02 per share for an aggregate purchase price of $4,988,300; closing is expected on or about August 12, 2025 and proceeds are intended for working capital and general corporate purposes. Troy M. Cox resigned from the board effective August 9, 2025, and the company stated the resignation was not due to any disagreement with the company.
Zymeworks (Nasdaq: ZYME) filed an 8-K announcing two material events.
- Amendment: The company removed the 19.99 % ownership cap from 5,086,521 pre-funded warrants originally sold to EcoR1 in December 2023.
- Exercise: On June 26 2025 the warrants were net-exercised at $0.0001; 5,086,480 common shares were issued on June 27 2025.
The exercise lifted the warrant overhang but adds ≈6.8 % to the basic share count, which now totals 74,844,505. Because the warrants were already deeply in-the-money, cash proceeds were immaterial (≈$509) and no additional capital was raised. EcoR1—already a >5 % holder with board representation—can now exceed the prior 19.99 % limit, increasing ownership concentration and voting power.
No financial statements or guidance were provided.